Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other 1

Conditions

Multiple Myeloma 4Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Stomatitis 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oncology Patients Receiving Chemotherapy 1Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Burkitt Lymphoma 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Diphenhydramine × Clear all
NCT03324113 2025-08-05

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Sanofi

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

NCT02606994 2019-02-06

TPvsM

Oral Defense, LLC

Phase 2 Terminated
1 enrolled
Other

Neoplasms, Stomatitis, Mucositis

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Eli Lilly and Company

Phase 2 Completed
68 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡